References
- Alberti C, Brun-Buisson C, Goodman SV, Guidici D, Granton J, Moreno R, . Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003;168:77–84.
- Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742–51.
- Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117–23.
- Silvestre J, Povoa P, Coelho L, Almeida E, Moreira P, Fernandes A, . Is C-reactive protein a good prognostic marker in septic patients? Intensive Care Med 2009;35:909–13.
- Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206–17.
- Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210–7.
- Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006;34:1996–2003.
- Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644–55.
- DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.
- Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, . Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296–327.
- Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, . The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010;36:222–31.
- Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, . Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 2005; 11:152–9.
- Balc IC, Sungurtekin H, Gurses E, Sungurtekin U, Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003;7:85–90.
- Bell K, Wattie M, Byth K, Silvestrini R, Clark P, Stachowski E, . Procalcitonin: a marker of bacteraemia in SIRS. Anaesth Intensive Care 2003;31:629–36.
- Viallon A, Guyomarc'h S, Marjollet O, Berger C, Carricajo A, Robert F, . Can emergency physicians identify a high mortality subgroup of patients with sepsis: role of procalcitonin. Eur J Emerg Med 2008;15:26–33.
- Chan YL, Tseng CP, Tsay PK, Chang SS, Chiu TF, Chen JC. Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit Care 2004;8: R12–20.
- Dahaba AA, Metzler H. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiol 2009;75:447–52.
- de Wolf HK, Gunnewiek JK, Berk Y, van den Ouweland J, de Metz M. Comparison of a new procalcitonin assay from Roche with the established method on the Brahms Kryptor. Clin Chem 2009;55:1043–4.
- Prieto B, Alvarez FV. Lack of transferability of results between procalcitonin assays. Clin Chem 2009;55:2226–7; author reply 2227–8.
- Karlsson S, Varpula M, Ruokonen E, Pettila V, Parviainen I, Ala-Kokko TI, . Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 2007;33:435–43.
- Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, . Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463–74.
- Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, . Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009;13:R83.